Polymeric RNAi Microsponge Delivery Simultaneously Targeting Multiple Genes for Novel Pathway Inhibition of Ovarian Cancer
Abstract
The first year of this award included the following tasks. Major Task 1 IACUC and ACURO Approval. Subtask 1 IACUC Approval. Months: 1 - 3. Subtask 2 Acuro Approval. Months: 3 - 6. Milestone(s) Achieved: We obtained the necessary approvals for performing animal experiments. Major Task 2: Synthesis and in vitro testing of single component RNAi-MS. Subtask 1: Synthesis of single component RNAi-MS. Months: 1-3. Subtask 2: Target product inhibition by single component RNAi. Months: 1-3. Subtask 3: Single component RNAi-MS mediated inhibition of in vitro cancer cell tumorigenic behavior. Months:-4-8. This task is still ongoing we will accomplish by end of this no cost extension year, 7/31/2017. Major Task 3: Synthesis and in vitro testing of multiple component RNAi-MS. Months 4-12. This task is in progress.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2016
- Accession Number
- AD1046768
Entities
People
- Michael Birrer
Organizations
- Massachusetts General Hospital